Reversing Diabetes Through New miRNA Drugs

Diabetes: Silent Killer

Diabetes (type 2 diabetes: T2D) is a silent killer—the disease can be present for years before a diagnosis is made. About 1.4 million new cases of diabetes are diagnosed in the United States every year. Blood glucose is fairly easily controlled by medication, but this does not prevent the long-term complications. Despite blood glucose control, damage occurs to virtually every organ system.

Limitations of Current Anti-Diabetic Drugs

Diabetes: Silent Killer

Reverse metabolic diseases using natural anti-diabetic and anti-obesity microRNAs

How It Works

miRNAs change gene expression, cell phenotype and function
We have discovered anti-diabetic and anti-obesity miRNAs that act on pancreatic cells, fat cells and gastrointestinal cells to reverse the pathology of type 2 diabetes.

Diabetic Therapeutic Pipeline

Lead identification:

RSVI-301/302 are anti-diabetic and anti-obese miRNAs

ID Study Indications
RSVI-301 Human cells, mice T2D, obesity, fatty liver disease, and gastroparesis
RSVI-302 Human cells, mice T1D, and gastroparesis
RSVI-303 Human cells, mice T2D, obesity, and gastroparesis
RSVI-304 Human cells, mice Prognostic and diagnostic markers for T2D